FDA Inspection 1296662 — Infusyn Therapeutics
The FDA completed an inspection of Infusyn Therapeutics on November 20, 2025 in Hackettstown, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Devices.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 20, 2025
- Fiscal Year
- 2026
- Product Type
- Devices
- Project Area
- Postmarket Assurance: Devices
- Location
- Hackettstown, NJ (United States)